Enzymit Raises $10M Series A for Cell-Free Bio-Production Technology
Enzymit, a synthetic biology company, has announced the close of its $10 million Series A funding round, led by Grove Ventures and Khosla Ventures, with participation from previous investors First Star Ventures and Sapir Venture Partners.
The Israeli startup is building a cell-free production platform that aims to make bioproduction faster, simpler, cost-effective, and scalable. The company leverages complex computational design and deep learning algorithms to create novel enzymes for real-world applications.
“For decades, bio-production has been limited by the search for natural enzymes that might fit industrial needs,” said Dr. Gideon Lapidoth, CEO and co-founder of Enzymit. “Our AI-powered platform changes this paradigm by designing entirely new enzymes tailored for specific production challenges. This enables us to create the molecules and materials that were previously unattainable or prohibitively costly to produce.”
>> Click here to read the full article originally published in CTech: